To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be faxed to 855-273-5735

OR

The patient may attach the completed form to the prescription and **mail** it to: Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

QUESTIONS? Call 1-877-880-7007

Step	Please complete patient and physician information (ple	ase print):			
1	Patient Name:				
•	Address:	Address:			
	Sponsor ID # Phone #:				
01		Secure Fax #:			
Step	Please complete the clinical assessment:				
2	1. Humira is the Department of Defense's preferred targeted biologic agent. Has the patient tried Humira?	□ Yes	🗆 No		
		proceed to question 2	proceed to question 4		
	2. Has the patient had an inadequate response to Humira?	□ Yes	🗆 No		
		proceed to question 5	proceed to question 3		
	3. Has the patient experienced an adverse reaction to Humira that is not expected to occur with the requested agent?	□ Yes	🗆 No		
		proceed to question 5	STOP		
			Coverage not approved		
	4. Does the patient have a contraindication to Humira (adalimumab)?	□ Yes	🗆 No		
		proceed to question 5	STOP		
			Coverage not approved		
	5. Cases of worsening congestive heart failure (CHF) and	□ Yes	🗆 No		
	new onset CHF have been reported with TNF blockers, including SIMPONI. Is the prescriber aware of this?	proceed to question 6	STOP Coverage not approved		
			Coverage not approved		

Golimumab (Simponi)

6. Is the patient 18 years of age or older?			☐ Yes proceed to question 7	☐ No STOP Coverage not approved	
7.	What is the indication or diagnosis?	□ moderate to severe active r	neumatoid arthritis – proceed t	o question 8	
	active psoriatic arthritis –		proceed to question 10		
		□ active ankylosing spondyli	tis – proceed to question 11		
		□ oderately to severely active t	ulcerative colitis – proceed to q	uestion 10	
		□ other indication or diagnosis – STOP: coverage not approved. Sign & date below.			
8.	Will Simponi be used in combination with		□ Yes	□ No	
	methotrexate?		proceed to question 9	STOP Coverage not approved	
9.	Does the patient have an active prescription for methotrexate?		□ Yes	🗆 No	
			proceed to question 12	STOP Coverage not approved	
10.	Has the patient had an inadequate response to non- biologic systemic therapy? (For example: methotrexate, aminosalicylates [e.g. sulfasalazine, mesalamine], corticosteroids, immunosuppressants [e.g. azathioprine], etc.)?		□ Yes	□ o	
			proceed to question 12	STOP	
				Coverage not approved	
11.	Has the patient had an inadequate response to at least two NSAIDS over a period of at least two months?		□ Yes	🗆 No	
			proceed to question 12	STOP Coverage not approved	
12.	Does the patient have evidence of a negative TB test result in the past 12 months (or TB is adequately managed)?		□ Yes	🗆 No	
			proceed to question 13	STOP Coverage not approved	
13.	Will the patient be receiving other targeted immunomodulatory biologics with Simponi, including but not limited to the following: Actemra, Cimzia, Cosentyx, Enbrel, Humira, Ilumya, Kevzara, Kineret, Olumiant, Orencia, Otezla, Remicade, Rituxan, Siliq, Stelara, Taltz, Tremfya or Xeljanz/Xeljanz XR?		□ Yes	□ No	
			STOP	Sign and date below	
			Coverage not approved		
	ortify the above is tr	up to the best of my know	ladaa Diasaa sign and a	lata:	

Step I certify the above is true to the best of my knowledge. Please sign and date:

3

Prescriber Signature

Date

[24 April 2019]